---
source_pdf: "https://drive.google.com/file/d/1AyRsyZDISZ5sDIiXicp1E-D5oD4ZBFni/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "Performant Investor Overview.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1AyRsyZDISZ5sDIiXicp1E-D5oD4ZBFni/view)

## Slide 1: INVESTOR PRESENTATION

# PERFORMANT
## INVESTOR PRESENTATION
### 2025 Company Overview

This document is for educational purposes only and may be updated and this information is provided “as is” without any expressed or implied warranty. Rights and obligations discussed in relation to the information in these materials are non-binding unless and until the parties enter into a signed, legally binding agreement.

## Slide 2: FORWARD LOOKING STATEMENTS

2

This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues and adjusted EBITDA in 2025 as well as illustrative future revenues and adjusted EBITDA margins, our commercial client growth strategy, our estimated revenue from commercial programs implemented, our ability to implement our first state government contract, our ability to scale our business through contract awards and implementations and the expected benefits of integrating workflow efficiencies, including through investment in artificial intelligence software, natural language processing technologies and other technology initiatives. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to generate revenue following long implementation periods associated with new customer contracts; client relationships and the Company's ability to maintain such client relationships; many of the Company's customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes; anticipated trends and challenges in the Company's business and competition in the markets in which it operates; the Company's indebtedness and compliance, or failure to comply, with restrictive covenants in the Company's credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company's ability to hire and retain employees with specialized skills that are required for its business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company's ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health emergencies, such as the COVID-19 pandemic, on the Company's business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company's operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company's third-party vendors and subcontractors; the adaptability of the Company's technology platform to new markets and processes; the Company's ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company's growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company's ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company's ability to comply with and adapt to industry regulations and compliance demands.

More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this presentation and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

© 2025 Performant. All rights reserved.
PERFORMANT

## Slide 3: Performant At A Glance

# PERFORMANT

| Metric | Value |
| :------------------------- | :------------ |
| **PHLT**                   | Nasdaq listed |
| **Market cap**             | ~$220M²       |
| **FTEs**                   | 900+          |
| **Serviceable Revenue Opportunity** | $4-5B         |

### Mission

“We are driven by a singular purpose—to transform the healthcare ecosystem by addressing more than $300 billion¹ in healthcare payment integrity. Our unwavering mission is to pioneer innovative solutions that redirect these funds towards enhancing patient care—an effort that aligns with the current administration's commitment to rooting out fraud, waste, and abuse.”

### What is Healthcare Payment Integrity?

*   Payment Responsibility
*   Clinical Appropriateness
*   Billing Accuracy
*   Contract Compliance

### Why does it exist?

*   Complex Coding
*   New Reimbursement Models
*   Disparate Data
*   Evolving Demographics

¹Source: JAMA "Waste in the US Health Care System: Estimated Costs and Potential for Savings
²As of 12/31/2024

© 2025 Performant. All rights reserved.
03

## Slide 4: Complex Industry Leads to Complex Solutions

# PERFORMANT
## Complex Industry Leads to Complex Solutions
Performant has the tools to address multiple payment errors and growing medical costs

| Problem Area              | Description                                                                                                                                                                                                                                                                                              |
| :------------------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **COMPLEX CODING**        | Multiple coding standards to adhere to                                                                                                                                                                                                                                                                   |
| **NEW REIMBURSEMENT MODELS** | Complicated contract arrangements                                                                                                                                                                                                                                                                        |
| **DISPARATE DATA**        | • Providers lack information about payer contracts and patient coverage<br>• Includes structured, unstructured and reference data                                                                                                                                                                            |
| **EVOLVING DEMOGRAPHICS** | Ageing demographic and growing population covered by insurance                                                                                                                                                                                                                                           |

**PERFORMANT**

### CLAIMS-BASED SERVICES

*   Is this billed and coded accurately?
*   Does this meet coding standards?
*   Is this contract compliant?

### ELIGIBILITY-BASED SERVICES

*   Is the correct party paying this claim?

© 2025 Performant. All rights reserved.
04

## Slide 5: Emerging Leader In Large And Growing Market

# PERFORMANT
## Emerging Leader In Large And Growing Market
Saved clients over $2B in last three years

### Projected National Health Expenditures¹

| Year | Projected Waste ($B) | Projected National Health Expenditures ($B) |
| :--- | :------------------- | :------------------------------------------ |
| 2023 | $1.2T                | $4.9T                                       |
| 2032 | $1.9T                | $7.8T                                       |

_Chart notes: ~20% of healthcare spend considered waste²_

### Healthcare Spend Breakdown

| Category                  | Percentage |
| :------------------------ | :--------- |
| Administrative Complexity | ~30%       |
| Inefficient Care          | ~35%       |
| Payment Integrity         | ~35%       |

_Note: Values are estimated from the stacked bar chart. Payment Integrity (bottom segment), Inefficient Care (middle segment), Administrative Complexity (top segment)._

¹Source: CMS, National Health Expenditure Data Projections - 2022
²Source: JAMA "Waste in the US Health Care System: Estimated Costs and Potential for Savings" - 2019

© 2025 Performant. All rights reserved.
05

## Slide 6: Market Sizing

# PERFORMANT
## Market Sizing
Claims processing is complex and inefficient, resulting in a meaningful market opportunity

### Market Funnel

| Category                       | Value     |
| :----------------------------- | :-------- |
| US Healthcare Spend            | ~$4.9T    |
| Waste in Healthcare¹           | ~$1.2T    |
| Payment Integrity Space        | ~$300B    |
| Addressable Opportunity²       | ~$25-30B  |
| Serviceable Revenue Opportunity³ | $4-5B     |

### $4-5B Serviceable Revenue Opportunity

| Segment            | Addressable Revenue |
| :----------------- | :------------------ |
| Federal Government | $500M-1B            |
| State Government   | $300-500M           |
| Commercial         | $3.2-3.5B           |

¹Source: JAMA "Waste in the US Health Care System: Estimated Costs and Potential for Savings" - 2019
²Management estimates of addressable inaccurate payments; exclusion examples include inhouse work and structurally not addressable
³Management estimates based on blended hit and fee rates

© 2025 Performant. All rights reserved.
06

## Slide 7: Significant Government Backbone

# PERFORMANT
## Significant Government Backbone
Started with Government and has become a bellwether for commercial payers

### Headline Federal Government Wins

*   **Q2 2025:** Expected decision on RAC Region 5 Re-compete and Opportunities for Regions 3 and 4
*   **October 2024:** Awarded New York State RAC contract – first state award
*   **DECEMBER 2022:** Re-awarded Medicare Secondary Payer Commercial Repayment Center (MSP CRC) contract
*   **MARCH 2022:** Awarded CMS RAC Region 2 for 8.5-years
*   **FEBRUARY 2022:** Announced HHS OIG IDIQ contract win
*   **APRIL 2021:** Re-awarded CMS RAC Region 1 for 8.5-years

### Led to Meaningful Commercial Traction

*   **33%** of 2024 Commercial Audit Savings Derived from our oldest RAC Region
*   **103** Commercial Implementations in last 36 months
*   Existing Commercial Clients grew **35%** on average since 2021

### Commercial vs Government Revenue Growth (45% 3-yr CAGR)

| Year | Commercial Revenue ($M) | Government Revenue ($M) |
| :--- | :---------------------- | :---------------------- |
| 2021 | $22.0                   | $55.5                   |
| 2022 | $36.5                   | $58.2                   |
| 2023 | $49.9                   | $56.5                   |
| 2024 | $66.9                   | $51.4                   |

_Linear (Commercial) is also shown on the chart, indicating a trend line for Commercial revenue growth._

© 2025 Performant. All rights reserved.
07

## Slide 8: Unique Approach

# PERFORMANT
## Unique Approach
Components required to effectively address payment integrity are complex—Performant offers a fresh approach

| Category                        | Details                                                                                                                                                                                                                                                                               |
| :------------------------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **CLIENT-CENTRIC BUSINESS MODEL** | • Shared savings business model<br>• Business process outsourcing<br>• Customizable solutions<br>• Focus on independence and quality                                                                                                                                                     |
| **PROPRIETARY DATA ASSETS**     | • 200+ million lives of eligibility data<br>• 10+ years of claims, rules, and contract data                                                                                                                                                                                            |
| **TECHNOLOGY STACK**            | • Purpose built for healthcare claims<br>• Advanced workflow, data analytics, and automation features                                                                                                                                                                                 |
| **INDUSTRY EXPERTISE AND INNOVATION** | • Medical directors, data analysts and payment integrity experts working together on real world solutions<br>• Concerted focus on developing new payment integrity concepts to increase client savings and reduce pain points |

© 2025 Performant. All rights reserved.
08

## Slide 9: Payment Integrity Landscape

# PERFORMANT
## Payment Integrity Landscape
High barriers to entry and consolidation results in less competition

The diagram illustrates five key interconnected areas defining the Payment Integrity Landscape, with Performant and other companies at the center.

**Key Areas:**
*   INFORMATION SECURITY
*   COMPLIANCE
*   DATA
*   TECHNOLOGY
*   INDUSTRY CREDIBILITY

**Companies in the center (implied competitors/peers):**
*   PERFORMANT
*   Optum
*   EXL
*   COTIVITI
*   gainwell

© 2025 Performant. All rights reserved.
09

## Slide 10: Multiple Avenues Of Growth

# PERFORMANT
## Multiple Avenues Of Growth
Successful track record of growth

### Land and Expand Example: (savings) +$100m

| Year | Savings ($M) |
| :--- | :----------- |
| 2016 | ~5           |
| 2017 | ~10          |
| 2018 | ~15          |
| 2019 | ~25          |
| 2020 | ~35          |
| 2021 | ~50          |
| 2022 | ~70          |
| 2023 | ~90          |
| 2024 | ~100+        |

_The chart shows a steady increase in savings over time._

### LAND AND EXPAND

**Expand Concepts**
*   ✓ Adopt new products

**Cross-Sell Services**
*   ✓ Sell audit services to existing eligibility clients

**Add Volume**
*   ✓ Add Medicare Advantage line of business
*   ✓ Add new region for a national payer

### NEW CLIENTS

**National (8M+ members)**
*   ✓ Currently have 5 of top 7 as clients

**Middle Market (500k-8M members)**
*   ✓ Currently have approximately 20% of market as clients

### ADJACENT MARKETS

*   ✓ Tackle other buckets of healthcare waste through M&A

### INNOVATION

*   ✓ SaaS development for smaller health plans
*   ✓ AI & NLP workflow gains

### Initial Partnership: National Payer

*   > Acute & DME Audit products for Medicare Advantage lives

### Growing Partnership

*   > 2019 - Added Managed Medicaid lives
*   > 2020 - Added new Audit product type
*   > 2020 - Cross-sold Eligibility product
*   > 2023 - Added new Eligibility product
*   > 2023 - Added new Audit product type

### New Clients

*   Implemented 4 new logos in 2024

© 2025 Performant. All rights reserved.
10

## Slide 11: Financial Highlights

# PERFORMANT
## Financial Highlights
Demonstrates Strong Growth and Operational Rigor

### STRONG HEALTHCARE REVENUE GROWTH: Healthcare Revenues

*   Strategic focus on healthcare growth and penetrating this massive market

| Year | Healthcare Revenues ($M) |
| :--- | :----------------------- |
| 2021 | $77.5                    |
| 2022 | $94.7                    |
| 2023 | $106.4                   |
| 2024 | $118.3                   |

### COST CONSCIOUS: Operational Expenses

*   Maintained operational discipline to generate efficiencies while growing

| Year | Operational Expenses ($M) |
| :--- | :------------------------ |
| 2021 | $125.7                    |
| 2022 | $116.1                    |
| 2023 | $119.9                    |
| 2024 | $132.5                    |

### INVESTED FOR FUTURE GROWTH: Commercial Implementations

*   Unique offering has led to strong sales, fueling tomorrow's growth

| Year | Commercial Implementations |
| :--- | :------------------------- |
| 2021 | 23                         |
| 2022 | 21                         |
| 2023 | 41                         |
| 2024 | 42                         |

### NIMBLE CAPITAL STRUCTURE: Debt on Balance Sheet

*   Financial flexibility to continue to grow

| Year | Debt on Balance Sheet ($M) |
| :--- | :------------------------- |
| 2021 | $20.0                      |
| 2022 | $19.5                      |
| 2023 | $5.0                       |
| 2024 | $8.0                       |

© 2025 Performant. All rights reserved.
11

## Slide 12: Performant Healthcare Evolution

# PERFORMANT
## Performant Healthcare Evolution
Started as a Division now a disruptive and scaling business

### Timeline

*   **2012: Innovation**
    *   ✓ Data Engine
    *   ✓ Product Development
    *   ✓ Government Footprint
    *   ✓ Commercial Entrance
*   **2021: Growth**
    *   ✓ Commercial Expansion
    *   ✓ Federal Government Re-awards
    *   ✓ State Government Entrance
    *   ✓ Further Product Development
*   **2025 On: Profitability**
    *   ✓ AI / NLP Roadmap
    *   ✓ Workflow Efficiencies
    *   ✓ Scale Contract Wins
    *   **Target 20% Adj. EBITDA Margins**

© 2025 Performant. All rights reserved.
12

## Slide 13: 2025 Adj. EBITDA Growth

# PERFORMANT
## 2025 Adj. EBITDA Growth
Discrete investments and Record new implementations masking profitability potential

| Category                      | Value ($M)         |
| :---------------------------- | :----------------- |
| **2024 Adj. EBITDA**          | $4.4M              |
| Operational Expansion         | +$9.1 - $12.1M     |
| Illustrative Adj. EBITDA      | $13.5 - $16.5M     |
| Commercial Implementations    | -$3.0 – $4.0M      |
| NY RAC Implementation         | -$1.5M             |
| Technology Investments        | -$1.0 – $2.0M      |
| **2025 Adj. EBITDA Guidance** | $8.0 – $9.0M       |

© 2025 Performant. All rights reserved.
13

## Slide 14: Margin Expansion

# PERFORMANT
## Margin Expansion
Path to Adj. EBITDA Margin Expansion

### Scaled adj. EBITDA margin potential built off scale and Efficiency Gains

| Stage                        | Revenue Range ($M) | Details                                                                                                                                                                                                                                           |
| :--------------------------- | :----------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **2025 Revenue Guidance**    | $131 - $135M       |                                                                                                                                                                                                                                                   |
| **Scale**                    |                    | Natural ability to grow record contract implementations currently subscale<br>• ✓ 100+ Commercial contracts implemented since 2022<br>• NY State RAC<br>• CMS RAC Region 2                                                                           |
| **Efficiency Gains**         |                    | Workflow and Technology Advancements<br>• AI / NLP Investments<br>• Workflow rationalization                                                                                                                                                        |
| **Target Future State**      | $150 - $160M       |                                                                                                                                                                                                                                                   |

© 2025 Performant. All rights reserved.
14

## Slide 15: Investment Highlights

# PERFORMANT
## Investment Highlights
Why Performant

*   **Best-in-class platform utilizes proprietary technology and AI to gain efficiencies and margin expansion**
    *   ~200M eligible lives in PHLT data assets
*   **Industry leading player in a multi-billion dollar, growing, highly monitored and increasingly complex healthcare payment integrity industry**
    *   $300B+ Payment Integrity Space
*   **Strong sales and implementation pipeline provides confidence and visibility into future revenue growth as continued market share gains demonstrate our ability to compete in a highly competitive market**
    *   45%+ 3-year commercial healthcare revenue CAGR
*   **Asset-light model with diverse, long-term client relationships that have resulted in attractive and visible operating leverage that can drive toward 20%+ EBITDA margins**
    *   ~300bps Adj. EBITDA margin expansion expected in 2025
*   **Dynamic management team with combined +100 years of experience and deep ties to government and private payers across the healthcare landscape with sticky relationships**
    *   900+ Professionals focused on payment integrity

© 2025 Performant. All rights reserved.
15

## Slide 16: APPENDIX

# APPENDIX

## Slide 17: Illustrative Contract Ramp

# PERFORMANT
## Illustrative Contract Ramp
Example of investment required to ramp with a contract ($/M)

### CLAIMS BASED (~47% of 2024 healthcare revenue)

| Stage           | Timeframe      | Revenue ($/M) | Gross Profit ($/M) | Margin | Description                                                                                                                                                                                                                                                |
| :-------------- | :------------- | :------------ | :----------------- | :----- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **INVESTMENT**  | 0-12 MONTHS    | $0.0          | $(0.2)             | 0%     | • Access to client systems<br>• Implement client policies and customizations<br>• Letter series and provider education<br>• Volume growth and recoveries begin to offset                                                                                       |
| **BREAK-EVEN**  | 12-30 MONTHS   | $0.3          | $0.0               | 0%     | • Scale volume and edits<br>• Adjust staffing needs                                                                                                                                                                                                        |
| **STEADY STATE** | 30+ MONTHS     | $1.0          | $0.4               | 40%    | • Optimize value through policy and content library edits<br>• Retraining staff needs                                                                                                                                                                      |

### ELIGIBILITY BASED (~53% of 2024 healthcare revenue)

| Stage           | Timeframe      | Revenue ($/M) | Gross Profit ($/M) | Margin | Description                                                                                                                                                                                                                                                |
| :-------------- | :------------- | :------------ | :----------------- | :----- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **INVESTMENT**  | 0-6 MONTHS     | $0.0          | $(0.1)             | 0%     | • Access to client data and systems<br>• Implement client into our propriety data assets<br>• Payer outreach, setup, and coordination<br>• Testing                                                                                                        |
| **BREAK-EVEN**  | 6-12 MONTHS    | $0.2          | $0.0               | 0%     | • Scale volume<br>• Adjust staffing needs                                                                                                                                                                                                                  |
| **STEADY STATE** | 12+ MONTHS     | $0.5          | $0.3               | 55%    | • Enrich data assets and expand payer connections<br>• Denial management and process optimization<br>• Retraining staff needs                                                                                                                                |

## Slide 18: Major Contract Wins and Ramp Illustration

# PERFORMANT
## Major Contract Wins and Ramp Illustration
Example of revenue and profitability ramp for major contract wins

_Legend:_
*   _Negative Operating Margins (Red pattern)_
*   _Revenue Progress (Black pattern)_
*   _Positive Operating Margins (Green pattern)_

| Contract / ACV                 | 2024 (Status)                                                               | 2025 (Status)                                                               | 2026 (Status)                                                               | 2027 (Status)                                                               | 2028 (Status)                                                               |
| :----------------------------- | :-------------------------------------------------------------------------- | :-------------------------------------------------------------------------- | :-------------------------------------------------------------------------- | :-------------------------------------------------------------------------- | :-------------------------------------------------------------------------- |
| **2022 Commercial Implementations** (20 @ ~$10m ACV) | Revenue Progress (partially filled)                                         | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             |
|                                | Negative Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   |
| **CMS RAC Region 2**           | Revenue Progress (partially filled)                                         | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             |
|                                | Negative Operating Margins (fully filled)                                   | Positive Operating Margins (partially filled)                               | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   |
| **2023 Commercial Implementations** (41 @ ~$18m ACV) | Revenue Progress (partially filled)                                         | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             |
|                                | Negative Operating Margins (fully filled)                                   | Positive Operating Margins (partially filled)                               | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   |
| **2024 Commercial Implementations** (42 @ ~$18m+ ACV) | Revenue Progress (partially filled, lighter)                                | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             |
|                                | Negative Operating Margins (fully filled)                                   | Negative Operating Margins (fully filled)                                   | Positive Operating Margins (partially filled)                               | Positive Operating Margins (fully filled)                                   | Positive Operating Margins (fully filled)                                   |
| **NY State Medicaid RAC**      | Revenue Progress (partially filled, lighter)                                | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             | Revenue Progress (fully filled)                                             |
|                                | Negative Operating Margins (partially filled, lighter than 2024 Commercial) | Negative Operating Margins (fully filled, more red than 2024 Commercial) | Positive Operating Margins (partially filled, less green than 2024 Commercial) | Positive Operating Margins (fully filled, more green than 2024 Commercial) | Positive Operating Margins (fully filled, more green than 2024 Commercial) |

## Slide 19: Payment Integrity: Medical Cost Savings

# PERFORMANT
## Payment Integrity: Medical Cost Savings
1 in 5 medical claims are processed incorrectly

### Top Flow (General Payment Integrity Process)

*   Intake & Prep
*   Check Eligibility
*   Select Provider
*   Determine Benefits
*   Validate Authorization
*   Price Claim
*   Remit Payment
*   Post Pay Audit

### Bottom Flow (Detailed Process)

**Path 1: CLAIMS AUDIT**
1.  **Client Claims Data**
2.  **CLAIMS AUDIT**
    *   Concepts to ID Claims
    *   Scoring & Selection
3.  Obtain Medical Records
4.  Audit Claims
    *   **Outcome 1:** Pre-pay: Cost Avoidance
    *   **Outcome 2:** Post-pay: Offset/Recovery

**Path 2: ELIGIBILITY**
1.  **Client Member Data**
2.  **ELIGIBILITY**
    *   Eligibility Matching
    *   Benefit Coordination
3.  Validate Coverage
    *   **Outcome 1:** Pre-pay: Report Primary
    *   **Outcome 2:** Post-pay: Bill Primary
    *   **Outcome 3:** Pre-pay: Cost Avoidance
    *   **Outcome 4:** Post-pay: Offset/Recovery

Note: Health Insurance Companies Process 1 in 5 Claims Wrong (capturebilling.com)

## Slide 20: Our Full Suite of Solutions

# PERFORMANT
## Our Full Suite of Solutions

### No Medical Records
*   COB & Eligibility
*   Provider Billing & Coding
*   Contract Compliance
*   System, Benefits & Policy

### Medical Records
*   DRG, Readmissions, Short Stay/Place of Service
*   Outpatient APC, APG, ASC and Other
*   DME, HIT, Home Health, Hospice
*   High-Cost Drugs, Clinical Labs, Genetic Testing

### Central Payment Integrity Focus Areas
*   Data Mining Advantage
*   MSP Advantage
*   TPL Advantage
*   Eligibility
*   Healthcare Solutions
*   Audit Advantage
*   Claims Audit

### Right-Side Outcomes
*   Premium Accuracy
*   Payer Reclamation
*   Provider Recovery
*   Cost Avoidance
*   Payer Reclamation
*   Rx Reclamation
*   Provider Recovery
*   Cost Avoidance
*   Aged or Referred Debt
*   Par/Non-Par
*   Medicare Supplement

### Claims or Audit-Based Reviews
*   Corrects claims that were billed inaccurately
*   **2024 Revenue:** $56.4MM
*   **3-Year CAGR:** ~23%

### Eligibility-Based Reviews
*   Identifies other insurance and coordinates coverage responsibility
*   **2024 Revenue:** $61.9MM
*   **3-Year CAGR:** ~8%

## Slide 21: CONSOLIDATED BALANCE SHEET

# CONSOLIDATED BALANCE SHEET
(In thousands, except per share amounts)

| Assets                                                 | As of December 31, 2024 | As of December 31, 2023 |
| :----------------------------------------------------- | :---------------------- | :---------------------- |
| **Current assets:**                                    |                         |                         |
| Cash and cash equivalents                              | $        9,292          | $        7,252          |
| Restricted cash                                        | —                       | 81                      |
| Trade accounts receivable, net of allowance for credit losses | 14,165                  | 17,584                  |
| Contract assets                                        | 10,876                  | 10,879                  |
| Prepaid expenses and other current assets              | 3,991                   | 3,651                   |
| Income tax receivable                                  | 34                      | 335                     |
| **Total current assets**                               | **38,358**              | **39,782**              |
| Property, equipment, and software, net                 | 14,021                  | 9,724                   |
| Goodwill                                               | 47,372                  | 47,372                  |
| Debt issuance costs                                    | 416                     | 631                     |
| Right-of-use assets                                    | 826                     | 531                     |
| Other assets                                           | 781                     | 990                     |
| **Total assets**                                       | **$      101,774**       | **$      99,030**       |
| **Liabilities and Stockholders' Equity**               |                         |                         |
| **Current liabilities:**                               |                         |                         |
| Accrued salaries and benefits                          | $        8,502          | $        7,924          |
| Accounts payable                                       | 482                     | 727                     |
| Other current liabilities                              | 2,091                   | 2,385                   |
| Contract liabilities                                   | 753                     | 493                     |
| Estimated liability for appeals and disputes           | 517                     | 601                     |
| Deferred asset acquisition payments                    | 1,243                   | —                       |
| Lease liabilities                                      | 383                     | 250                     |
| **Total current liabilities**                          | **13,971**              | **12,380**              |
| Long-term loan payable                                 | 8,000                   | 5,000                   |
| Deferred asset acquisition payments                    | 2,686                   | —                       |
| Lease liabilities                                      | 462                     | 295                     |
| Other liabilities                                      | 156                     | 648                     |
| **Total liabilities**                                  | **25,275**              | **18,323**              |
| Commitments and contingencies                          |                         |                         |
| **Stockholders' equity:**                              |                         |                         |
| Common stock, $0.0001 par value. Authorized, 500,000 shares at December 31, 2024 and 2023, respectively; issued and outstanding, 78,309 and 76,920 shares at December 31, 2024 and 2023, respectively | 8                       | 8                       |
| Additional paid-in capital                             | 151,688                 | 146,001                 |
| Accumulated deficit                                    | (75,197)                | (65,302)                |
| **Total stockholders' equity**                         | **76,499**              | **80,707**              |
| **Total liabilities and stockholders' equity**         | **$      101,774**       | **$      99,030**       |

© 2025 Performant. All rights reserved.
PERFORMANT

## Slide 22: CONSOLIDATED STATEMENTS OF OPERATIONS

# CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)

|                                                     | **Three Months Ended December 31,** | **Twelve Months Ended December 31,** |
| :-------------------------------------------------- | :-------------------- | :------------------- | :-------------------- | :------------------- |
| **(In thousands)**                                  | **2024**              | **2023**             | **2024**              | **2023**             |
| Revenues                                            | $           34,766    | $          32,567     | $          122,981     | $          113,743    |
| **Operating expenses:**                             |                       |                      |                       |                      |
| Salaries and benefits                               | 26,710                | 23,308               | 100,431               | 90,447               |
| Other operating expenses                            | 8,745                 | 7,349                | 32,050                | 29,424               |
| Total operating expenses                            | **35,455**            | **30,657**           | **132,481**           | **119,871**          |
| Income (loss) from operations                       | (689)                 | 1,910                | (9,500)               | (6,128)              |
| Gain on sale of certain recovery contracts          | —                     | —                    | —                     | 3                    |
| Interest expense                                    | (307)                 | (785)                | (1,105)               | (1,974)              |
| Interest income                                     | 99                    | 154                  | 359                   | 240                  |
| Loss before (benefit from) income taxes             | (897)                 | 1,279                | (10,246)              | (7,859)              |
| Provision for (benefit from) income taxes           | (399)                 | 24                   | (351)                 | (340)                |
| Net income (loss)                                   | $           (498)     | $          1,255      | $          (9,895)     | $          (7,519)    |
| **Net income (loss) per share attributable to common shareholders** |                       |                      |                       |                      |
| Basic                                               | $           (0.01)    | $          0.02       | $          (0.13)      | $          (0.10)     |
| Diluted                                             | $           (0.01)    | $          0.02       | $          (0.13)      | $          (0.10)     |
| **Weighted average shares**                         |                       |                      |                       |                      |
| Basic                                               | 78,300                | 76,896               | 77,500                | 76,156               |
| Diluted                                             | 78,300                | 77,361               | 77,500                | 76,156               |

© 2025 Performant. All rights reserved.
PERFORMANT

## Slide 23: CONSOLIDATED STATEMENTS OF CASH FLOWS

# CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)

|                                                                          | **For the Years Ended December 31,** |
| :----------------------------------------------------------------------- | :----------------------------------- | :----------------------------------- |
| **(In thousands)**                                                       | **2024**                             | **2023**                             |
| **Cash flows from operating activities:**                                |                                      |                                      |
| Net loss                                                                 | $                (9,895)            | $                (7,519)            |
| *Adjustments to reconcile net loss to net cash provided by operating activities:* |                                      |                                      |
| Loss on disposal of assets                                               | 63                                   | 129                                  |
| Depreciation and amortization                                            | 6,598                                | 5,187                                |
| Right-of-use assets amortization                                         | 333                                  | 1,526                                |
| Stock-based compensation                                                 | 5,881                                | 3,936                                |
| Amortization of debt issuance costs                                      | 230                                  | 347                                  |
| Loss on debt extinguishment                                              | —                                    | 510                                  |
| Gain on sale of certain recovery contracts                               | —                                    | (3)                                  |
| *Changes in operating assets and liabilities:*                           |                                      |                                      |
| Trade accounts receivable                                                | 3,419                                | (1,790)                              |
| Contract assets                                                          | 3                                    | 581                                  |
| Prepaid expenses and other current assets                                | (340)                                | 14                                   |
| Income tax receivable                                                    | 301                                  | 2,788                                |
| Other assets                                                             | 190                                  | 10                                   |
| Accrued salaries and benefits                                            | 578                                  | 986                                  |
| Accounts payable                                                         | (245)                                | (535)                                |
| Contract liabilities and other current liabilities                       | (34)                                 | 188                                  |
| Estimated liability for appeals and disputes                             | (84)                                 | (505)                                |
| Lease liabilities                                                        | (328)                                | (1,759)                              |
| Other liabilities                                                        | (492)                                | (231)                                |
| **Net cash provided by operating activities**                            | **6,178**                            | **3,860**                            |
| **Cash flows from investing activities:**                                |                                      |                                      |
| Purchase of property, equipment, and software                            | (7,010)                              | (4,143)                              |
| Proceeds from sale of certain recovery contracts                         | —                                    | 3                                    |
| **Net cash used in investing activities**                                | **(7,010)**                          | **(4,140)**                          |
| **Cash flows from financing activities:**                                |                                      |                                      |
| Repayment of long-term loan payable                                      | —                                    | (19,500)                             |
| Debt issuance costs paid                                                 | (15)                                 | (1,156)                              |
| Taxes paid related to net share settlement of stock awards               | (194)                                | (196)                                |
| Borrowings from revolving loan                                           | 3,000                                | 5,000                                |
| **Net cash provided by (used in) financing activities**                  | **2,791**                            | **(15,852)**                         |
| **Net increase (decrease) in cash, cash equivalents and restricted cash** | **1,959**                            | **(16,132)**                         |
| Cash, cash equivalents and restricted cash at beginning of year          | 7,333                                | 23,465                               |
| **Cash, cash equivalents and restricted cash at end of year**            | **$                9,292**            | **$                7,333**            |
| **Reconciliation of the consolidated statements of cash flows to the consolidated balance sheets:** |                                      |                                      |
| Cash and cash equivalents                                                | $                9,292               | $                7,252               |
| Restricted cash                                                          | —                                    | 81                                   |
| **Total cash, cash equivalents and restricted cash at end of period**    | **$                9,292**            | **$                7,333**            |
| **Non-cash investing activities:**                                       |                                      |                                      |
| Deferred asset acquisition payments                                      | $                3,929               | $                —                   |
| **Supplemental disclosures of cash flow information:**                   |                                      |                                      |
| Cash (received) paid for income taxes                                    | $                  (94)              | $                (3,052)             |
| Cash paid for interest                                                   | $                  670               | $                1,291               |

© 2025 Performant. All rights reserved.

## Slide 24: RECONCILIATION OF NON-GAAP RESULTS

# RECONCILIATION OF NON-GAAP RESULTS
(In thousands, except per share amounts)

### Reconciliation of Adjusted EBITDA:

|                                                    | **Three Months Ended December 31,** | **Year Ended December 31,** |
| :------------------------------------------------- | :-------------------- | :------------------- | :-------------------- | :------------------- |
| **(In thousands)**                                 | **2024**              | **2023**             | **2024**              | **2023**             |
| Net income (loss)                                  | $           (498)     | $          1,255      | $          (9,895)     | $          (7,519)    |
| Provision for (benefit from) income taxes          | (399)                 | 24                   | (351)                 | (340)                |
| Interest expense (1)                               | 307                   | 785                  | 1,105                 | 1,974                |
| Interest income                                    | (99)                  | (154)                | (359)                 | (240)                |
| Stock based compensation                           | 1,759                 | 1,121                | 5,881                 | 3,936                |
| Depreciation and amortization                      | 1,354                 | 1,382                | 6,598                 | 5,187                |
| Severance expenses (3)                             | (8)                   | 100                  | 656                   | 346                  |
| Non-core operating expenses (4)                    | 701                   | 15                   | 737                   | 52                   |
| Gain on sale of certain recovery contracts (5)     | —                     | —                    | —                     | (3)                  |
| **Adjusted EBITDA**                                | **$           3,117**   | **$          4,528**    | **$          4,372**    | **$          3,393**   |

**Footnotes:**
(1) Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
(2) Represents amortization of debt issuance costs related to our Credit Agreement and prior credit agreement. _(Note: This footnote refers to "Amortization of debt issuance costs" which is not explicitly in the EBITDA table but is part of the broader reconciliation context.)_
(3) Represents severance expenses incurred in connection with a reduction in force for our nonhealthcare services.
(4) Represents payments primarily related to legacy recovery business.
(5) Represents gain on the sale of certain non-healthcare recovery contracts.
(6) Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
(7) The Net loss for the three months ended December 31, 2024 was ($498), while the computation of adjusted net income results in adjusted net income of $1,321. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2024 includes dilutive common share equivalents of 1,584 added to the basic weighted average shares of 78,300. Similarly, net income for the three months ended December 31, 2023 was $1,255, and the computation of adjusted net income results in adjusted net income of $3,597. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2023 includes dilutive common share equivalents of 465 added to the basic weighted average shares of 76,896.

© 2025 Performant. All rights reserved.
PERFORMANT

## Slide 25: RECONCILIATION OF NON-GAAP RESULTS (CONT'D)

# RECONCILIATION OF NON-GAAP RESULTS (CONT'D)
(In thousands, except per share amounts)

### Reconciliation of Adjusted Net Income (Loss):

|                                                  | **Three Months Ended December 31,** | **Year Ended December 31,** |
| :----------------------------------------------- | :-------------------- | :------------------- | :-------------------- | :------------------- |
| **(In thousands)**                               | **2024**              | **2023**             | **2024**              | **2023**             |
| Net income (loss)                                | $           (498)     | $          1,255      | $          (9,895)     | $          (7,519)    |
| Stock based compensation                         | 1,759                 | 1,121                | 5,881                 | 3,936                |
| Amortization of debt issuance costs (2)          | 57                    | 601                  | 230                   | 857                  |
| Severance expenses (3)                           | (8)                   | 100                  | 656                   | 346                  |
| Non-core operating expenses (4)                  | 701                   | 15                   | 737                   | 52                   |
| Gain on sale of certain recovery contracts (5)   | —                     | —                    | —                     | (3)                  |
| Tax adjustments (6)                              | (690)                 | 505                  | (2,064)               | (1,427)              |
| **Adjusted net income (loss)**                   | **$           1,321**   | **$          3,597**    | **$          (4,455)**  | **$          (3,758)**  |

**Footnotes:** _(These footnotes are identical to those on Slide 24.)_
(1) Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
(2) Represents amortization of debt issuance costs related to our Credit Agreement and prior credit agreement.
(3) Represents severance expenses incurred in connection with a reduction in force for our nonhealthcare services.
(4) Represents payments primarily related to legacy recovery business.
(5) Represents gain on the sale of certain non-healthcare recovery contracts.
(6) Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
(7) The Net loss for the three months ended December 31, 2024 was ($498), while the computation of adjusted net income results in adjusted net income of $1,321. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2024 includes dilutive common share equivalents of 1,584 added to the basic weighted average shares of 78,300. Similarly, net income for the three months ended December 31, 2023 was $1,255, and the computation of adjusted net income results in adjusted net income of $3,597. Therefore, the calculation of the adjusted earnings per diluted share for the three months ended December 31, 2023 includes dilutive common share equivalents of 465 added to the basic weighted average shares of 76,896.

© 2025 Performant. All rights reserved.
PERFORMANT

## Slide 26: QUARTERLY AND ANNUAL REVENUE CONTRIBUTION BY LINE OF BUSINESS

# QUARTERLY AND ANNUAL REVENUE CONTRIBUTION BY LINE OF BUSINESS
(In thousands, except per share amounts)

### For the Year Ended December 31, 2024

| (in thousands)                  | March 31, 2024 | June 30, 2024 | September 30, 2024 | December 31, 2024 | Year Ended December 31, 2024 |
| :------------------------------ | :------------- | :------------ | :----------------- | :---------------- | :--------------------------- |
| Eligibility-based               | $     13,388   | $    14,264    | $        16,070    | $     18,138      | $      61,860                |
| Claims-based                    | 12,412         | 13,661        | 14,217             | 16,141            | 56,431                       |
| **Healthcare Total**            | **25,800**     | **27,925**    | **30,287**         | **34,279**        | **118,291**                  |
| Customer Care / Outsourced Services | 1,534          | 1,437         | 1,232              | 487               | 4,690                        |
| **Total**                       | **$     27,334** | **$    29,362** | **$        31,519** | **$     34,766**  | **$      122,981**           |

### For the Year Ended December 31, 2023

| (in thousands)                  | March 31, 2023 | June 30, 2023 | September 30, 2023 | December 31, 2023 | Year Ended December 31, 2023 |
| :------------------------------ | :------------- | :------------ | :----------------- | :---------------- | :--------------------------- |
| Eligibility-based               | $     12,480   | $    14,131    | $        18,165    | $     16,403      | $      61,179                |
| Claims-based                    | 10,412         | 9,798         | 10,325             | 14,730            | 45,265                       |
| **Healthcare Total**            | **22,892**     | **23,929**    | **28,490**         | **31,133**        | **106,444**                  |
| Recovery                        | 19             | 14            | —                  | —                 | 33                           |
| Customer Care / Outsourced Services | 2,818          | 1,542         | 1,472              | 1,434             | 7,266                        |
| **Total**                       | **$     25,729** | **$    25,485** | **$        29,962** | **$     32,567**  | **$      113,743**           |

### For the Year Ended December 31, 2022

| (in thousands)                  | March 31, 2022 | June 30, 2022 | September 30, 2022 | December 31, 2022 | Year Ended December 31, 2022 |
| :------------------------------ | :------------- | :------------ | :----------------- | :---------------- | :--------------------------- |
| Eligibility-based               | $     14,214   | $    12,417    | $        13,142    | $     13,511      | $      53,284                |
| Claims-based                    | 9,150          | 9,339         | 10,377             | 12,516            | 41,382                       |
| **Healthcare Total**            | **23,364**     | **21,756**    | **23,519**         | **26,027**        | **94,666**                   |
| Recovery                        | 118            | 7             | 41                 | 75                | 241                          |
| Customer Care / Outsourced Services | 3,601          | 3,918         | 3,618              | 3,140             | 14,277                       |
| **Total**                       | **$     27,083** | **$    25,681** | **$        27,178** | **$     29,242**  | **$      109,184**           |

© 2025 Performant. All rights reserved.
PERFORMANT